Logo do repositório
 
Publicação

Optimizing the use of cabotegravir plus rilpivirine long-acting therapy in HIV care : evidence, implementation, and unanswered questions

2025-07Contributo em revista Acesso aberto
Ver registo simples
datacite.subject.fosCiências Médicas::Ciências da Saúde
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorGeretti, Anna Maria
dc.contributor.authorBoffito, Marta
dc.contributor.authorBonora, Stefano
dc.contributor.authorBraun, Patrick
dc.contributor.authorCharpentier, Charlotte
dc.contributor.authorGarcia, Federico
dc.contributor.authorGhosn, Jade
dc.contributor.authorGomes, Perpétua
dc.contributor.authorMarcelin, Anne-Geneviève
dc.contributor.authorMesplède, Thibault
dc.contributor.authorParczewski, Milosz
dc.contributor.authorRing, Kyle
dc.contributor.authorSantoro, Maria Mercedes
dc.contributor.authorSolas, Caroline
dc.contributor.authorWolf, Eva
dc.contributor.authorOrkin, Chloe
dc.date.accessioned2026-05-14T15:28:05Z
dc.date.available2026-05-14T15:28:05Z
dc.date.issued2025-07
dc.description.abstractCabotegravir plus rilpivirine long-acting (CAB + RPV-LA) injectable therapy marks a major milestone in HIV care, offering an efficacious, well-tolerated alternative to daily oral antiretroviral treatment. This article reviews data from pivotal trials and observational studies of CAB + RPV-LA, addressing emerging questions and highlighting key research priorities. We examine factors influencing virological outcomes, including issues related to HIV subtype, archived drug resistance, body mass index, and pharmacokinetics, and discuss challenges related to hepatitis B virus immunity and infection, pregnancy, and adherence. We outline strategies to address barriers to implementation, advocating for a tailored approach to maximize the potential of CAB + RPV-LA in improving outcomes across diverse populations with HIV.eng
dc.identifier.citationAnna Maria Geretti, Marta Boffito, Stefano Bonora, Patrick Braun, Charlotte Charpentier, Federico Garcia, Jade Ghosn, Perpetua Gomes, Anne-Geneviève Marcelin, Thibault Mesplède, Milosz Parczewski, Kyle Ring, Maria Mercedes Santoro, Caroline Solas, Eva Wolf, Chloe Orkin, Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions, Open Forum Infectious Diseases, Volume 12, Issue 7, July 2025, ofaf368, https://doi.org/10.1093/ofid/ofaf368
dc.identifier.doi10.1093/ofid/ofaf368
dc.identifier.issn2328-8957
dc.identifier.urihttp://hdl.handle.net/10400.26/63144
dc.language.isoeng
dc.peerreviewedyes
dc.publisherOxford University Press
dc.relation.hasversionhttps://doi.org/10.1093/ofid/ofaf368
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectHBV
dc.subjectlong-acting
dc.subjectpharmacokinetics
dc.subjectresistance
dc.subjectsubtype
dc.titleOptimizing the use of cabotegravir plus rilpivirine long-acting therapy in HIV care : evidence, implementation, and unanswered questionseng
dc.typecontribution to journal
dspace.entity.typePublication
oaire.citation.issue7
oaire.citation.startPageofaf368
oaire.citation.titleOpen Forum Infectious Diseases
oaire.citation.volume12
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Artigo_PGomes_2025_06.pdf
Tamanho:
1018.73 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.85 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

EM - Artigos Científicos